Genetic alterations to NFE2L2 and KEAP1 lead to constitutive activation of NRF2, that occurs in 30% of lung squamous cell carcinoma and 25% of lung adenocarcinoma [101,102,103]. This evidence concerns the gene NFE2L2 and lung adenocarcinoma.